The Acquired Metabolic Disorders of the Nervous System, Ischemic-Hypoxic Encephalopathy
Adams & Victors Principles of Neurology Chp 40, pg 1133, Ropper, A.H.,et al, 2014
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014
Neuropsychiatric Changes Precede Classic Motor Symptoms in ALS and Do Not Affect Survival
Neurol 82:149-155, Mioshi, E.,et al, 2014
Addition of Hyperacute MRI Aids in Patient Selection, Decreasing the Use of Endovascular Stroke Therapy
Stroke 45:467-472, Wisco, D.,et al, 2014
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Opportunistic Infections of the Retina in Patients with Aquaporin-4 Antibody Disease
JAMA Neurol 71:1429-1432, George, J.S.,et al, 2014
Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 71:1372-1378, Huh, S.Y.,et al, 2014
CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapsing-Remitting MS
Neurol 83:1780-1788, Limmroth, V.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Motor Neurone Disease
BMJ 349:g4052, Nageshwaran, S.,et al, 2014
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014
Neurological Manifestation of Recreational Fatal and Near-Fatal Diethylene Glycol Poisonings
Medicine 93:e62, Imam, Y.Z.B.,et al, 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
IgG4-Related Hypertrophic Pachymeningitis
JAMA Neurol 71:785-793, Lu, L.X.,et al, 2014
Intensive Care Unit Admission in Multiple Sclerosis
Neurol 82:2112-2119, Marrie, R.A.,et al, 2014
Balos Concentric Sclerosis
Lancet Neurol 13:740-746, Hardy, T.A. & Miller, D.H., 2014
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke
NEJM 370:1091-1100,1159, Juttler, E.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Superficial Abdominal Reflex
NEJM 370:e29, Baden, L.R., 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Co-Occurrence of Multiple Cerebral Infarctions Due to Hypercoagulability Associated with Malignancy and Meningeal Carcinomatosis as the Initial Manifestation of Gastric Cancer
BMC Neurol 14:160, Kawasaki,A.,et al, 2014
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013
Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Interdependence and Contributions of Sun Exposure and Vitamin D to MRI Measures in Multiple Sclerosis
JNNP 84:1075-1081, 1066, Zivadinov, R.,et al, 2013
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through Breastfeeding
JAMA Neurol 70:1367-1374, Veiby, G.,et al, 2013
Sturge-Weber Syndrome
MedLink Neurology, July, Comi, A.M., 2013
Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013
Clinical Spectrum of CNS Aquaporin-4 Autoimmunity
Neurol 78:1179-1185, Kim, S.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013
Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013
Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013